In the private insurance market, 57.4 million adults under 65 could be potentially eligible for GLP-1 drugs Over 2 in 5 (42%) adults under 65 with private insurance could be eligible for GLP-1 drugs, based on current Food and Drug Administration (FDA) indications
In clinical trials, adults who used Wegovy alongside diet and lifestyle changes lost an average of 1415% of their body weight over one year.* Individual results vary based on factors such as dosage, adherence, lifestyle habits, and overall health
Ultra-Pure Formula Made with arugula (high N-O, low oxalate) and third-party tested for undetectable oxalates
Is semaglutide approved for treating MASH
Set up manually: Episode Notes On todays episode, hosts Candice Lim and Kate Lindsay are joined by writer Virgie Tovar, whose latest podcast, GLP-1 Truth Serum, explores the predatory nature of GLP-1 marketing, and companies attempts to target plus-size creators